Key terms
About CLNN
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CLNN news
Mar 20
7:21am ET
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Clene (CLNN) and Jazz Pharmaceuticals (JAZZ)
Mar 15
1:45pm ET
Buy Rating Affirmed for Clene Amid Positive ALS Drug Data and Market Dynamics
Mar 15
8:20am ET
Clene announces peer-reviewed publication on CNM-Au8
Mar 13
8:09am ET
Clene expects cash to fund operations into 4Q24
Mar 13
8:09am ET
Clene reports 2023 EPS (47c), consensus (45c)
Mar 11
8:40am ET
Analysts Offer Insights on Healthcare Companies: Clene (CLNN), REPRO-MED Systems (KRMD) and Bioventus (BVS)
Feb 29
10:25am ET
Buy Rating Affirmed for Clene’s CNM-Au8 on Promising Long-Term Clinical Outcomes
Feb 29
8:23am ET
Clene Announces Breakthrough CNM-Au8 Treatment Results
Feb 29
8:16am ET
Clene presents clinical results of CNM-Au8 30mg treatment
Feb 22
11:37am ET
Buy Rating Affirmed for Clene Amidst Strong Clinical Data and Financial Stability
Feb 22
8:12am ET
Clene’s CNM-Au8 Shows Promise in ALS Survival Rates
Feb 22
8:07am ET
Clene reports ‘significant’ survival results from two analyses of CNM-Au8
Jan 09
6:38am ET
Buy Rating Affirmed: Clene’s CNM-Au8 Shows Promising Efficacy in MS Treatment Study
Jan 08
7:27am ET
Clene reports new CNM-Au8 results from VISIONARY-MS trial
Dec 22
1:10pm ET
Analysts Offer Insights on Healthcare Companies: Clene (CLNN) and Karuna Therapeutics (KRTX)
Dec 21
8:36am ET
Optimistic Buy Rating for Clene’s Stock Backed by Promising ALS Survival and Biomarker Data
Dec 21
7:09am ET
Clene announces new data from HEALEY ALS Platform Trial
Dec 21
7:05am ET
Clene announces FDA said NfL reduction insufficient for accelerated approval
No recent news articles are available for CLNN
No recent press releases are available for CLNN
CLNN Financials
Key terms
Ad Feedback
CLNN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CLNN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range